• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?血液系统恶性肿瘤患者对新冠疫苗的细胞反应：无反应者的新希望？
Leuk Lymphoma. 2022 Mar;63(3):743-746. doi: 10.1080/10428194.2021.1998485. Epub 2021 Oct 28.
2
SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.SARS-CoV-2 疫苗在血液系统恶性肿瘤患者中的疗效：进一步研究的实用要点。
Oncologist. 2022 Nov 3;27(11):e917-e918. doi: 10.1093/oncolo/oyac173.
3
Blunted humoral response after mRNA vaccine in patients with haematological malignancies.血液系统恶性肿瘤患者接种mRNA疫苗后体液免疫反应减弱。
Lancet Haematol. 2021 Aug;8(8):e540-e542. doi: 10.1016/S2352-3026(21)00197-6. Epub 2021 Jul 2.
4
Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres.COVID-19 疫苗第三剂可恢复丧失保护性抗体滴度的血液系统恶性肿瘤患者的免疫应答。
Br J Haematol. 2022 May;197(3):302-305. doi: 10.1111/bjh.18073. Epub 2022 Feb 28.
5
Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination.血液系统恶性肿瘤患者的治疗、血清转化率和 SARS-CoV-2 疫苗接种。
Oncologist. 2022 Nov 3;27(11):e916. doi: 10.1093/oncolo/oyac169.
6
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.血液恶性肿瘤患者 COVID-19 两剂疫苗系列的免疫原性：三例突破性感染报告。
Cancer Control. 2022 Jan-Dec;29:10732748211070720. doi: 10.1177/10732748211070720.
7
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
8
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.SARS-CoV-2疫苗接种后，血液系统恶性肿瘤的黑人和西班牙裔人群血清转化率较高。
Leuk Lymphoma. 2022 Oct;63(10):2484-2488. doi: 10.1080/10428194.2022.2074988. Epub 2022 May 20.
9
COVID-19 vaccines for patients with haematological conditions.用于血液系统疾病患者的新冠疫苗。
Lancet Haematol. 2021 May;8(5):e312-e314. doi: 10.1016/S2352-3026(21)00073-9. Epub 2021 Mar 31.
10
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.SARS-CoV-2 原发感染和突破感染的癌症患者：对患者护理的影响。
Best Pract Res Clin Haematol. 2022 Sep;35(3):101384. doi: 10.1016/j.beha.2022.101384. Epub 2022 Sep 29.

引用本文的文献

1
Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients.比较癌症患者对 COVID-19 疫苗接种的细胞和体液免疫应答动力学。
Viruses. 2023 Jun 26;15(7):1439. doi: 10.3390/v15071439.
2
Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency.免疫缺陷个体中 COVID-19 疫苗的细胞和体液免疫原性与 COVID-19 疾病严重程度。
Front Immunol. 2023 Mar 24;14:1131604. doi: 10.3389/fimmu.2023.1131604. eCollection 2023.
3
Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.血液系统恶性肿瘤患者对新冠疫苗接种的免疫反应：一篇综述
Chonnam Med J. 2023 Jan;59(1):24-30. doi: 10.4068/cmj.2023.59.1.24. Epub 2023 Jan 25.
4
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.一项系统评价和荟萃分析：成人血液恶性肿瘤患者对 SARS-CoV-2 疫苗首剂和第 2 剂的免疫应答。
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.
5
Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences.癌症患者接种疫苗后的细胞免疫反应——既往与当前经验综述
Vaccines (Basel). 2022 Jan 25;10(2):182. doi: 10.3390/vaccines10020182.

Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

作者信息

Saad Albichr Imane, De Greef Julien, Van Den Neste Eric, Poiré Xavier, Havelange Violaine, Vekemans Marie-Christiane, Bailly Sarah, Yombi Jean-Cyr, Mzougui Samy, Scohy Anaïs, Kabamba-Mukadi Benoît

机构信息

Department of Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

Department of Internal Medicine and Infectious Disease, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

出版信息

Leuk Lymphoma. 2022 Mar;63(3):743-746. doi: 10.1080/10428194.2021.1998485. Epub 2021 Oct 28.

DOI:10.1080/10428194.2021.1998485
PMID:34706604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8567276/
Abstract
摘要